Dale Greiner to Ligands
This is a "connection" page, showing publications Dale Greiner has written about Ligands.
Connection Strength
0.148
-
Wagar EJ, Cromwell MA, Shultz LD, Woda BA, Sullivan JL, Hesselton RM, Greiner DL. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol. 2000 Jul 01; 165(1):518-27.
Score: 0.040
-
Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol. 2000 Jan 01; 164(1):512-21.
Score: 0.038
-
Foy TM, McIlraith M, Masters SR, Dunn JJ, Rossini AA, Shultz LD, Hesselton RA, Wagar EJ, Lipsky PE, Noelle RJ, Greiner DL. Blockade of CD40-CD154 interferes with human T cell engraftment in scid mice. Cell Transplant. 1998 Jan-Feb; 7(1):25-35.
Score: 0.034
-
Chang C, Goel HL, Gao H, Pursell B, Shultz LD, Greiner DL, Ingerpuu S, Patarroyo M, Cao S, Lim E, Mao J, McKee KK, Yurchenco PD, Mercurio AM. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the a6B?1 integrin to sustain breast cancer stem cells. Genes Dev. 2015 Jan 01; 29(1):1-6.
Score: 0.027
-
Zheng XX, Markees TG, Hancock WW, Li Y, Greiner DL, Li XC, Mordes JP, Sayegh MH, Rossini AA, Strom TB. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol. 1999 Apr 15; 162(8):4983-90.
Score: 0.009